Li et al. reported that NT5DC3 can be used as a biomarker to discriminate patients with type 2 diabetes (T2D) and T2D-induced colon cancer from healthy volunteers by detecting the expression level of NT5DC3 in the blood 13. This evidence concerns the gene NT5DC3 and colonic neoplasm.